The primary objective of this study is to determine the safety and the immunogenicity of
extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV)
to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801,
C-1802, or C-1803.